Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $11.7 million.

  • Janux Therapeutics' Accumulated Expenses rose 70.14% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 70.14%. This contributed to the annual value of $11.7 million for FY2024, which is 58.17% up from last year.
  • Janux Therapeutics' Accumulated Expenses amounted to $11.7 million in FY2024, which was up 58.17% from $7.4 million recorded in FY2023.
  • Janux Therapeutics' 5-year Accumulated Expenses high stood at $11.7 million for FY2024, and its period low was $751,000 during FY2020.
  • Over the past 3 years, Janux Therapeutics' median Accumulated Expenses value was $8.2 million (recorded in 2022), while the average stood at $9.1 million.
  • In the last 5 years, Janux Therapeutics' Accumulated Expenses spiked by 403.20% in 2021 and then decreased by 9.68% in 2023.
  • Yearly analysis of 5 years shows Janux Therapeutics' Accumulated Expenses stood at $751,000 in 2020, then surged by 403.20% to $3.8 million in 2021, then soared by 116.43% to $8.2 million in 2022, then declined by 9.68% to $7.4 million in 2023, then surged by 58.17% to $11.7 million in 2024.